Дослідження зрозуміло

Назад до стрічки
PubMed
Опис окремого випадку

Висока важливість

7 жовт. 2026 р.

From Refractory Iron Deficiency Anemia to the Diagnosis of Hereditary Hemorrhagic Telangiectasia Type 1: A Case Report

Відкрити першоджерело

Чому це важливо

This case illustrates the importance of considering HHT in patients with unexplained anaemia and bleeding. It also suggests that new treatments like bevacizumab might help patients suffering from severe bleeding related to HHT, but more research is needed.

Мета

This case report aims to highlight the diagnosis of Hereditary Hemorrhagic Telangiectasia (HHT) in a patient who has a long history of iron deficiency anaemia and recurrent bleeding.

Результати

The patient showed significant improvement after treatment, including better haemoglobin levels and reduced bleeding. Genetic testing confirmed the diagnosis of HHT type 1.

Методи

This is a case study of a 70-year-old man with chronic anaemia, who underwent various examinations including genetic testing, endoscopy, and imaging to identify blood vessel issues linked to HHT. The patient received treatment for bleeding lesions and systemic therapy.

Обмеження

This is a single case report, meaning it reflects only one patient’s experience and may not apply to everyone with HHT. Further studies are needed to understand the effectiveness of treatments like bevacizumab in different cases.

Для вашого лікаря:

PMID: 42999694

DOI: 10.7759/cureus.117613

Анотація

Показано англійською

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal-dominant vascular disorder characterized by mucocutaneous telangiectasias and visceral arteriovenous malformations (AVMs) resulting in recurrent epistaxis, gastrointestinal bleeding, iron deficiency anemia, and complications related to pulmonary and cerebral vascular shunting. We report the case of a 70-year-old man with a 20-year history of refractory iron deficiency anemia requiring frequent blood transfusions and intravenous iron therapy who presented with recurrent epistaxis, melena, exertional dyspnea, and bilateral lower-limb edema. Examination demonstrated multiple telangiectasias involving the fingertips, nasal mucosa, oral cavity, and tongue. Endoscopic evaluation revealed multiple bleeding telangiectatic lesions involving the stomach, jejunum, and colon, with argon plasma coagulation performed for hemostasis. Contrast-enhanced computed tomography demonstrated multisystem AVMs involving the lungs, liver, and spleen, while no cerebral AVM was identified. Contrast echocardiography demonstrated a delayed appearance of microbubbles in the left atrium after five cardiac cycles, consistent with an intrapulmonary shunt. Genetic testing identified a pathogenic variant in the endoglin (ENG) gene, confirming HHT type 1. A significant pulmonary arteriovenous malformation was treated with transcatheter embolization. In view of severe recurrent bleeding and transfusion-dependent anemia despite local measures, systemic bevacizumab was initiated at 5 mg/kg every two weeks for six doses, followed by monthly maintenance therapy. The patient subsequently demonstrated a marked clinical response, with improvement in hemoglobin levels and cessation of melena, without an infusion-related adverse reaction. This case highlights the importance of recognizing HHT in patients with longstanding unexplained iron deficiency anemia and recurrent bleeding from multiple vascular territories and demonstrates the potential role of systemic bevacizumab in patients with severe HHT-associated bleeding.